Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCB-1201
- Development stage
- Preclinical
- Lead developer
- Vaxcell-Bio Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VCB-1201 is an investigational Chimeric Antigen Receptor - Marrow Infiltrating Lymphocyte (CAR-MIL) cell therapy being developed by Vaxcell Bio for the treatment of solid tumors and hematologic malignancies. Unlike conventional CAR-T therapies that utilize T cells derived from peripheral blood, VCB-1201 utilizes Marrow Infiltrating Lymphocytes (MILs) harvested from the bone marrow. MILs are naturally enriched for central memory T cells and possess a broad repertoire of endogenous T-cell receptors (TCRs) capable of recognizing multiple tumor-associated antigens. By genetically engineering these MILs to express a Chimeric Antigen Receptor (CAR), VCB-1201 aims to combine the specific, high-affinity targeting of CAR technology with the polyclonality and long-term persistence of bone marrow-derived memory T cells. The therapy is currently in the preclinical stage of development.
- Other names
- Vax-CAR-MIL
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on VCB-1201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCB-1201.